Phase 2 Schizophrenia trials recruiting now

All Schizophrenia trials, every phase

Other phases for Schizophrenia

Phase 2 Schizophrenia trials

• A Clinical Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Schedule in Patients With Schizophrenia
  NCT06821945 · Phase: Phase 2 · Ages: 19 Years and older · Sex: All (male and female) · 2 locations
• A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
  NCT07459647 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 42 locations
• A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia
  NCT07423546 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 50 Years · Sex: All (male and female) · 1 location
• A Study of Brenipatide in Adult Participants With Schizophrenia
  NCT07410507 · Phase: Phase 2 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 103 locations
• A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
  NCT07145918 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 7 locations
• A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
  NCT06540833 · Phase: Phase 2 · Ages: 55 Years and older · Sex: All (male and female) · 67 locations
• A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
  NCT06887192 · Phase: Phase 2 · Ages: 55 Years to 90 Years · Sex: All (male and female) · 110 locations
• A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
  NCT07191483 · Phase: Phase 2 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 15 locations
• Acetazolamide for Treatment Resistant Schizophrenia
  NCT04887792 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 2 locations
• An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults
  NCT03094429 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 1 location
• Combination of NMDA-enhancing and Anti-inflammatory Treatments for Schizophrenia
  NCT04917302 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resistant Schizophrenia
  NCT05240976 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia
  NCT04959201 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia
  NCT03794076 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Dual Modulation of Sigma-1 and NMDA Receptors in the Treatment of Schizophrenia
  NCT06574360 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer
  NCT05052853 · Phase: Phase 2 · Ages: 13 Years to 45 Years · Sex: All (male and female) · 1 location
• Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder
  NCT06939088 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 2 locations
• Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia
  NCT07288333 · Phase: Phase 2 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 6 locations
• Low Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy
  NCT06529029 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 90 Years · Sex: All (male and female) · 1 location
• Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia
  NCT05778591 · Phase: Phase 2 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location
• MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction
  NCT06191965 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 35 Years · Sex: All (male and female) · 3 locations
• Monotherapy of an NMDA Enhancer for Schizophrenia
  NCT04745143 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia
  NCT06021197 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Neurotransmitters in Treatment Resistant Schizophrenia Patients With add-on Sodium Benzoate
  NCT06340789 · Phase: Phase 2 · Ages: 20 Years to 55 Years · Sex: All (male and female) · 1 location
• No Guts No Glory Probiotics
  NCT07606014 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 3 locations
• Ocrelizumab for Psychosis by Autoimmunity
  NCT03971487 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 35 Years · Sex: All (male and female) · 1 location
• Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine
  NCT07185815 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 64 Years · Sex: All (male and female) · 6 locations
• Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
  NCT06376734 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 6 locations
• Sex Differences in NMDA-enhancing Treatment of Schizophrenia
  NCT07122895 · Phase: Phase 2 · Ages: 20 Years to 65 Years · Sex: All (male and female) · 1 location
• Study of ALTO-101 in Patients With Schizophrenia
  NCT06502964 · Phase: Phase 2 · Ages: 21 Years to 55 Years · Sex: All (male and female) · 14 locations
• Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
  NCT07467993 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 16 locations
• Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia
  NCT07680946 · Phase: Phase 2 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 2 locations
• Synbiotic Compound to Reduce Symptoms of Schizophrenia
  NCT04226898 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Tolerability of MDMA in Schizophrenia
  NCT05770375 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location

Common questions

What does Phase 2 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.